Shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) have garnered an average recommendation of “Moderate Buy” from six analysts currently covering the biopharmaceutical company, according to a report from MarketBeat.com. Among these analysts, one has issued a sell rating, while five recommend buying the stock. The consensus target price for Aclaris over the next year stands at $9.75.
Several analysts have commented on the stock recently. On October 20, 2023, HC Wainwright reaffirmed a “buy” rating, setting a target price of $16.00. Conversely, Weiss Ratings maintained a “sell (d-)” rating in a research note released on the same day.
Stock Performance and Financial Overview
On Monday, Aclaris shares opened at $2.88. The company possesses a market capitalization of approximately $312.05 million, with a price-to-earnings ratio of -2.09 and a beta of 0.41. Over the past year, the stock has fluctuated significantly, recording a low of $1.05 and a high of $3.47. Currently, the 50-day moving average price is $2.76, while the 200-day moving average stands at $2.11.
Aclaris Therapeutics recently announced its quarterly earnings results on November 6, 2023. The firm reported a loss of ($0.12) per share, marginally exceeding analysts’ expectations of ($0.13). The company’s revenue for the quarter reached $3.30 million, outperforming forecasts of $1.59 million. Analysts predict that Aclaris will report an earnings per share (EPS) of ($0.82) for the current fiscal year.
About Aclaris Therapeutics
Founded in 2016 and based in Malvern, Pennsylvania, Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, developing, and commercializing innovative small-molecule therapies aimed at treating dermatologic diseases and related rare disorders. The company’s pipeline includes various candidates targeting chronic inflammatory skin conditions and non-melanoma skin lesions.
Key development programs include ATI-50002, a topical treatment designed for molluscum contagiosum removal; ATI-50003 for resolving common warts; ATI-1501, an oral JAK1/2 inhibitor addressing pruritic disorders; and ATI-450, an oral MK2 inhibitor for inflammatory conditions. Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance its clinical and preclinical candidates.
For ongoing updates and insights, interested parties can subscribe to receive a daily summary of news and analysts’ ratings related to Aclaris Therapeutics through MarketBeat.com.
